At some point, almost everyone on a GLP-1 medication asks the question. Maybe it's when they hit their goal weight. Maybe it's when the pharmacy bill arrives. Maybe it's when someone says "you can't stay on that forever, can you?"
The answer to what happens when you stop is important, and the research is clear enough to give you an honest one. It's not what most people want to hear — but understanding it upfront leads to better decisions than discovering it later.
What the clinical trials show
The STEP 1 extension study tracked what happened when participants stopped semaglutide 2.4mg after 68 weeks of treatment. Within one year of stopping, participants regained approximately two-thirds of the weight they had lost. The cardiometabolic improvements — blood pressure, blood sugar, cholesterol — also reversed substantially (Wilding et al., 2022).
The SURMOUNT-4 trial told a similar story with tirzepatide. Participants who stopped tirzepatide after 36 weeks and switched to placebo regained a significant portion of their lost weight, while those who continued treatment maintained their losses (Aronne et al., 2024).
A post-hoc analysis of SURMOUNT-4 went further, quantifying exactly how weight regain reversed the cardiometabolic benefits — the improvements in liver markers, blood pressure, and inflammatory markers degraded in proportion to the amount of weight regained (Horn et al., 2025).
A narrative review pooling data across liraglutide, semaglutide, and tirzepatide discontinuation studies confirmed this as a consistent class-wide pattern: weight regain after stopping GLP-1 medications is the norm, not the exception (Quarenghi et al., 2025).
These numbers aren't comfortable. But they're not unique to GLP-1 medications either. Weight regain after stopping any weight-loss intervention — from dieting to surgery — is extremely common. The body's weight regulation system is persistent and powerful. It fights to return to its previous set point through increased hunger hormones, decreased metabolic rate, and neurological changes that drive food-seeking behaviour.
Why regain happens
GLP-1 medications work by acting on your brain's appetite and reward centres. They suppress hunger, enhance satiety, reduce food noise, and slow gastric emptying. When you stop the medication, those signals return to their pre-treatment state. The hunger comes back. The food noise comes back. The satiety signal weakens.
This isn't failure. It's biology. Obesity is increasingly understood as a chronic neuroendocrine condition — not a character flaw, not a lack of willpower, not something you can permanently fix with a temporary course of medication and then maintain through determination alone.
The analogy doctors increasingly use: treating obesity with a short course of GLP-1 medication and then stopping is like treating high blood pressure with medication for a year and then stopping. The condition hasn't been cured. The symptoms were managed. Remove the management and the condition returns.
Does everyone regain?
Not identically. The two-thirds figure is an average. Some people regain more. Some people regain less. A subset appears to maintain significant loss after stopping — though this group is in the minority.
Factors that appear to influence post-cessation outcomes include how much lifestyle change was established during treatment, the degree of resistance training and muscle preservation achieved, the metabolic health improvements gained, the duration of treatment before stopping, and individual differences in the underlying biology of appetite regulation.
People who used their time on GLP-1 medications to fundamentally restructure their eating habits, establish consistent exercise routines, and build muscle mass appear to fare somewhat better after stopping — though even in this group, some regain is typical.
The emerging consensus
The medical community is increasingly moving toward viewing GLP-1 medications as long-term treatments for a chronic condition. Major obesity medicine guidelines now explicitly state that anti-obesity medications may need to be continued indefinitely to maintain their benefits — just as blood pressure medications, cholesterol medications, or diabetes medications are continued long-term.
This shift in perspective is important because it changes the question. Instead of "when can I stop?" the more useful question becomes "how do I sustain this treatment long-term?" That leads to conversations about cost management, dose optimisation, insurance coverage, and the arrival of generic semaglutide — all of which are making long-term treatment more feasible.
If you do decide to stop
Some people will choose to stop, or need to stop, for legitimate reasons — cost, side effects, pregnancy planning, personal preference, or medical direction. If that's your situation, here's what helps.
Taper if your doctor agrees. Stopping abruptly from a high dose may be harder than stepping down gradually. This isn't universally recommended, but some clinicians prefer a gradual reduction.
Have your nutrition and exercise habits locked in before you stop, not after. The medication was suppressing your appetite. When it's gone, the habits you built while appetite was managed are your primary defence.
Front-load protein. As hunger returns, protein-rich meals will help you feel fuller than carbohydrate-heavy ones. This is the single most impactful dietary habit to have in place.
Continue resistance training. Muscle is metabolically active — it burns more calories at rest than fat. The muscle you built or preserved during treatment raises your baseline metabolic rate, which provides some buffer against regain.
Monitor without obsessing. Weigh yourself regularly. Track trends, not daily fluctuations. If you see a clear upward trajectory developing, address it early — either through renewed lifestyle focus or a conversation with your doctor about resuming treatment.
Accept that some regain is physiologically normal. The goal after stopping shouldn't be maintaining every last pound of loss — it should be maintaining as much health benefit as possible while acknowledging that your body is recalibrating.
The bottom line
The data is clear: most people who stop GLP-1 medications regain a substantial portion of their lost weight. This isn't a failure of the medication or the person — it's the nature of a chronic condition being managed rather than cured.
Understanding this upfront helps you make better decisions. If you're starting, know that this may be a long-term commitment. If you're considering stopping, prepare your lifestyle foundation first and set realistic expectations. And if regain happens, know that restarting treatment is always an option — the medication works the second time too.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from. Here are the most relevant and impactful studies we referenced:
-
Wilding et al. (2022) — The STEP 1 extension study tracking outcomes after semaglutide discontinuation: participants regained approximately two-thirds of lost weight within one year, with reversal of cardiometabolic improvements. The most cited study on GLP-1 weight regain. Read the study on PubMed
-
Aronne et al. (2024) — The SURMOUNT-4 trial demonstrating that continued tirzepatide treatment maintained weight loss while switching to placebo led to significant regain, establishing the evidence for long-term treatment. Read the study on PubMed
-
Horn et al. (2025) — Post-hoc analysis of SURMOUNT-4 quantifying exactly how weight regain reverses cardiometabolic benefits including liver markers, blood pressure, and inflammatory markers. Read the analysis on PMC
-
Quarenghi et al. (2025) — Narrative review pooling weight regain data across liraglutide, semaglutide, and tirzepatide discontinuation studies, confirming regain as a consistent class-wide pattern. Read the review on PubMed
-
Rubino et al. (2021) — The STEP 4 trial showing that continuing semaglutide after an initial 20-week run-in maintained weight loss, while switching to placebo led to regain — early evidence supporting long-term use. Read the study on PubMed
These studies consistently demonstrate that GLP-1 medications manage rather than cure obesity, supporting the medical consensus that long-term treatment may be necessary to maintain benefits.
Medical Disclaimer: Never stop a prescribed medication without consulting your healthcare provider. This guide is for informational purposes only.